Your shopping cart is empty.

CLOPIpgx

Pharmacogenetics DNA test for clopidogrel
Adequate response to clopidogrel treatment.
CLOPIpgx analyzes genetic polymorphisms involved in treatment with clopidogrel (Plavix®, Iscover®) to ensure its efficiency and prevent thrombosis. Clopidogrel prevents blood platelet aggregation, primarily prescribed to people who have suffered a hear...
CLOPIpgx analyzes genetic polymorphisms involved in treatment with clopidogrel (Plavix®, Iscover®) to ensure its efficiency and prevent thrombosis. Clopidogrel prevents blood platelet aggregation, primarily prescribed to people who have suffered a heart attack. Clopidogrel is a prodrug and certain SNPs interfere with the formation of the active drug.  
175,00

Sample type:

Saliva

Delivery period:

30 - 40 days from sample receipt.
Last update of the document Jun, 10/06/2019 - 13:17

Clopidogrel DNA test

Clopidogrel is an antiplatelet agent. It is considered the first option for the preventive treatment of the risk of thrombosis.

It is a prodrug, that is, it has no direct pharmacological action, and it is an enzyme of the liver CYP2C19 that converts it into its active form. The synthesis of the CYP2C19 enzyme depends on the CYP2C19 gene.

30-35% of the population have genetic polymorphisms that affect the activity of the enzyme, to a greater or lesser extent, and therefore these people will respond to treatment in a different way than expected.

People with genetic polymorphisms that produce an enzyme without activity (12% population), have a high risk of thrombosis, so should seek an alternative treatment.

People with intermediate activity (20% population) will need double dose to obtain the desired effect.

International guidelines support the study of these polymorphisms. The FDA (USA), requires to inform in the brochures of this drug, the recommendation that the genetic polymorphisms of the patient should be studied, prior to their prescription, in order to know the effectiveness of the medication, which depends on the activation of the metabolite by the enzyme CYP2C19.

An activation failure may result in a less effective treatment.

Interpretation of the report in Polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

 

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Info producto mobile

Profile Information

Clopidogrel DNA test

Clopidogrel is an antiplatelet agent. It is considered the first option for the preventive treatment of the risk of thrombosis.

It is a prodrug, that is, it has no direct pharmacological action, and it is an enzyme of the liver CYP2C19 that converts it into its active form. The synthesis of the CYP2C19 enzyme depends on the CYP2C19 gene.

30-35% of the population have genetic polymorphisms that affect the activity of the enzyme, to a greater or lesser extent, and therefore these people will respond to treatment in a different way than expected.

People with genetic polymorphisms that produce an enzyme without activity (12% population), have a high risk of thrombosis, so should seek an alternative treatment.

People with intermediate activity (20% population) will need double dose to obtain the desired effect.

International guidelines support the study of these polymorphisms. The FDA (USA), requires to inform in the brochures of this drug, the recommendation that the genetic polymorphisms of the patient should be studied, prior to their prescription, in order to know the effectiveness of the medication, which depends on the activation of the metabolite by the enzyme CYP2C19.

An activation failure may result in a less effective treatment.

Interpretation of the report in Polytherapy

In this report, the "green" labeling of a certain drug with the patient's genes indicates that it can be prescribed in the standard dose conditions disclosed in the prospectus or those recommended by the physician. This applies in the case of monotherapy.

However, if the patient takes several medications, which is very common, although in the report would appear in "green" can cause adverse effects due to possible interactions between them, which can sometimes be severe, either by toxicity or by therapeutic failure.

Drugs are chemicals that may interfere the normal metabolism of other drugs. Interferences that are also applicable to the chemical substances of various medicinal plants and food supplements.

Consequently, the whole of the medication, together with the consumer products or life habits of the patient, must undergo an evaluation of pharmacological interactions.

Consulting g-Nomic® Pharmacogenetics interpretation software, before prescribing, is an effective aid to avoid most adverse effects or therapeutic failures due to medication.

g-Nomic® interrelates all drugs, herbs, nutritional supplements and lifestyle, with the patient's genes. It also advises the most appropriate dose to prescribe.

This text has been translated automatically using an electronic translator, so the Spanish version should prevail. Please check in case of doubt.

 

Sample type and process to follow

You will receive the sample collection kit. You can request additional kits if you need it.

Sample collection kit content:
You will get a box with sample collection kit. Within the kit you will find:

  1. Saliva collector.
  2. Instructions for the sample collection.
  3. Informed consent sheet and application form.
  4. Security bag to enter the sample for shipment.
  5. Envelope bag.

Process to follow:

  1. Follow the instructions for collecting the sample.
  2. After obtaining the sample, include it in the return envelope, remember to put into the informed consent sheet and the application form.
  3. No shipping costs on Spanish territory.
  4. An email confirmation will be sent when your sample si received.
  5. When the study will be completed you will receive a new e-mail to inform you that your report is already available in "My results".

Documentación